Navigation Links
Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma
Date:5/6/2009

CASTRES, France, May 6 /PRNewswire/ -- Pierre Fabre Dermatologie, specialised department of Pierre Fabre Laboratories, is proud to announce the launch of a set of clinical trials following the signature of an exclusive and worldwide licence agreement on July 10th 2008 with the University of Bordeaux. The contract covers the development, production and marketing of a paediatric beta-blocker for the treatment of severe infantile haemangioma with the intention of obtaining NDA-approval (New Drug Application) both for Europe and the USA. Patents were also applied for in this indication.

The efficacy of beta-blockers on haemangioma was discovered by Dr. Christine Leaute- Labreze, dermatologist in Pr. Alain Taieb's department in Bordeaux. "Effectiveness of this treatment has been demonstrated in several hundred children throughout the world. Rigorous clinical trials are, however, yet to be conducted to ascertain the efficacy and tolerance of this new therapeutic strategy, hence this agreement with Pierre Fabre Dermatologie, which would ensure safety and availability of the treatment."

This therapeutic breakthrough has been widely talked about, not only during scientific conferences but also through professional and general-interest press.

"This is a major discovery that will bring true therapeutic advance to patients affected by this highly apparent disease, which can be very severe and can have a strong impact on their quality of life and that of their parents. For this reason, we are highly honoured to have signed this agreement with the University of Bordeaux on severe haemangioma," specifies Jacques Fabre, General Manager of Pierre Fabre Dermocosmetique.

About haemangioma:

Infantile haemangioma refers to a vascular tumour highly prevalent in infants, with a 10% concurrency rate. Haemangioma occurs in the first months of life and is located on the face in 60% of cases
'/>"/>

SOURCE Pierre Fabre SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status
2. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
3. Evotec Starts Phase II in Smoking Cessation with EVT 302
4. Synosia Starts Phase II Efficacy Trial For Rufinamide
5. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
6. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
7. Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
8. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
9. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
10. Gerresheimer Starts Process to Sell off its Business Segment of Technical Plastics
11. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 New spin-out from ... Cambridge Innovation Capital and Johnson & Johnson Development ... company focused on harnessing the potential of circulating ... and treatment, today announced it has raised £4m ... and including Cambridge Innovation Capital and Johnson & ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Pearl's Premium ... breakthrough in drought tolerant grass seed this week with ... seed. The announcement coincides with the fact that it ... Spring as many believe. , As of the ... and favorable reviews by industry experts and the media ...
(Date:9/22/2014)... , September 22, 2014 ... the addition of the "Global Biotechnology Reagents ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Biotechnology reagents ... to a system to detect and examine another ... generally used in laboratories to prepare, collect, and ...
(Date:9/22/2014)... it is to stop bleeding, are very simple. They ... the physical environment around them, researchers at Emory and ... with greater stiffness by increasing their stickiness, the degree ... components of the clotting system, the researchers found. , ... in that they are able to sense the physical ...
Breaking Biology Technology:Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4Pearl's Premium Ultra Low Maintenance Lawn Seed Announces A Major Breakthrough In Drought Tolerant Grass Seed 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 3Platelets modulate clotting behavior by 'feeling' their surroundings 2
... Texas, Jan. 5, 2012  Healthpoint Biotherapeutics today announced that ... Robert Bancroft, Executive Vice President, Strategic and Commercial Development, ... products and its R&D pipeline at the upcoming J.P. ... January 9th, at 9:30 am (PST) at the Westin ...
... Biosystems, Inc. (OTCBB:WGBS), an emerging genomic analysis company, today ... presentation at the 5 th Annual OneMedForum San ... Francisco, Calif., January 9-12, 2012. The company ... beginning at 10:00 a.m. Pacific Time.  The presentation will ...
... 5, 2012  ZyGEM Corp. Ltd., a developer and ... DNA and other nucleic acids, and the US ... today announced the signing of a Cooperative Research ... simplified sample processing solutions for biothreat agents.  The ...
Cached Biology Technology:WaferGen to Present Corporate Overview at 5th Annual OneMedForum San Francisco 2012 2ZyGEM and USAMRIID Sign CRADA for Development of Simplified Sample Processing Solutions for Biothreat Agents 2ZyGEM and USAMRIID Sign CRADA for Development of Simplified Sample Processing Solutions for Biothreat Agents 3
(Date:9/23/2014)... times more carbon than the atmosphere and small ... big effect on atmospheric greenhouse gas concentrations. A ... Change concludes that climate warming does not ... carbon storage, despite increases in ecosystem productivity. ... Research Ecologist Dr. Christian Giardina, with the agency,s ...
(Date:9/23/2014)... temperature on insects to predict how climate change will ... shows for the first time that insects, fear of ... fast they grow. , "In other words, it,s less ... that shape the growth, survival and distribution of insects." ... an Arctic postdoctoral researcher at Dartmouth. , The ...
(Date:9/23/2014)... Eureka Therapeutics, Inc. announced today that the Company has ... new funding will be used to expand the Company,s ... clinical development. New investor Yuan Capital led the round, ... including Acorn Campus Ventures, Suma Venture and Harbinger Venture ... and development of fully-human antibodies engineered to mimic the ...
Breaking Biology News(10 mins):Study helps assess impact of temperature on belowground soil decomposition 2Insects' fear limits boost from climate change, Dartmouth study shows 2
... SAN DIEGO, Calif. (March 10, 2009)Attempts to treat ... patients with below-the-knee angioplasty are still thwarted by ... site of angioplasty or stenting), the need for ... disease, leading to tissue death (gangrene) and amputation. ...
... SAN DIEGO, Calif. (March 10, 2009)The use of common ... (ABI)along with traditional risk scoring systemssuch as the Framingham ... in thousands of individuals who are not originally thought ... say researchers at the Society of Interventional Radiology,s 34th ...
... March 9 Explorations Group Inc. (OTC Bulletin ... letter of intent to acquire Daniel R. Smith & Associates, ... total of $4.2 million to be paid in a combination ... Intent, EXGI President David Coriaty stated "the acquisition of DRSA ...
Cached Biology News:Promising 3-year data: Saving limbs with drug-eluting stents 2Promising 3-year data: Saving limbs with drug-eluting stents 3Simple test helps predict heart attack risk 2Simple test helps predict heart attack risk 3Explorations Group Announces Letter of Intent to Acquire Specialty Lighting Company 2
IHC detection kit for PCNA in cells and tissues...
Request Info...
... Immunogen: Synthetic peptide derived from ... WNT1 protein. Specificity: Reacts with ... Reactivity: Human Mouse (positive controls: ... cell lysates and mouse Mouse-1 cell ...
... Nick Translation System is ideal for both ... Nick Translation System: Provides five pre-mixed ... incorporation Yields >10 8 cpm/g ... DNA to monitor the performance of the ...
Biology Products: